Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAR0o1ohiVJtw8fINpZemrMlfQypJpnHrWCNDW-YbdBsA#assertion>. }
Showing items 1 to 44 of
44
with 100 items per page.
- subject C0011777 "dexamethasone" assertion.
- object C4552904 "risk" assertion.
- object C0035647 "risk" assertion.
- object C0869039 "dose" assertion.
- object C0178602 "dose" assertion.
- object C3811910 "combination" assertion.
- object C1947911 "combination" assertion.
- object C0205195 "combination" assertion.
- object C0439064 "multi" assertion.
- object C0205250 "high" assertion.
- subject C0439228 "day" assertion.
- object C0439228 "day" assertion.
- subject C0205171 "Single" assertion.
- object C0040808 "regimens" assertion.
- subject C1561539 "day" assertion.
- object C1561539 "day" assertion.
- subject C1561538 "day" assertion.
- object C1561538 "day" assertion.
- subject C1549113 "Single" assertion.
- subject C0332173 "day" assertion.
- object C0332173 "day" assertion.
- subject C0087136 "Single" assertion.
- subject C0037179 "Single" assertion.
- predicate select?q=TRIPLE_UID:gd6dd4qm-TRIPLE-ABSTRACT-11 "recommend" assertion.
- object C5202936 "high" assertion.
- object C5200928 "high" assertion.
- object C4522209 "high" assertion.
- object C4321237 "high" assertion.
- object C3889660 "high" assertion.
- object C3887512 "high" assertion.
- object C2700149 "high" assertion.
- object C1700730 "netupitant" assertion.
- object C1561958 "high" assertion.
- object C1561957 "high" assertion.
- object C1299351 "high" assertion.
- object C0220578 "palonosetron" assertion.
- object C0171023 "olanzapine" assertion.
- object C0013973 "emetogenic" assertion.
- object C0008838 "cisplatin" assertion.
- triple label "Single - day dexamethasone dosing recommended over multi - day dosing for regimens with high emetogenic risk excluding high - dose cisplatin , preferably in combination with palonosetron , netupitant , and olanzapine" assertion.
- sentence label "Single-day dexamethasone dosing is recommended over multi-day dosing for regimens with high emetogenic risk excluding high-dose cisplatin, preferably in combination with palonosetron, netupitant, and olanzapine." assertion.
- version value "1" assertion.
- assertion wasGeneratedBy "S&T TWOC project version 1" assertion.
- Triple-UID select?q=TRIPLE_UID:gd6dd4qm-TRIPLE-ABSTRACT-11 "gd6dd4qm-TRIPLE-ABSTRACT-11" assertion.